Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 4.13B P/E - EPS this Y -7.80% Ern Qtrly Grth -
Income -392.99M Forward P/E -9.21 EPS next Y -5.20% 50D Avg Chg -17.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg -11.00%
Dividend N/A Price/Book 11.80 EPS next 5Y - 52W High Chg -36.00%
Recommedations 3.00 Quick Ratio 8.63 Shares Outstanding 181.43M 52W Low Chg 16.00%
Insider Own 15.30% ROA -27.08% Shares Float 76.42M Beta 1.55
Inst Own 86.68% ROE -89.69% Shares Shorted/Prior 6.02M/4.88M Price 26.33
Gross Margin - Profit Margin - Avg. Volume 520,117 Target Price 43.40
Oper. Margin - Earnings Date Feb 23 Volume 2,422,080 Change -14.09%
About Cerevel Therapeutics Holdings,

Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, develops various therapies for neuroscience diseases in the United States. It is developing Emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures in epilepsy or focal epilepsy, as well as in phase 1 trial to treat panic symptoms model. The company's products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist that is in phase 3 clinical trial for the treatment of early- and late-stage Parkinson's disease; CVL-871, a selective dopamine D1/D5 partial agonist, which is in Phase 2a clinical trial to treat dementia-related apathy; and CVL-354, a selective kappa-opioid receptor antagonist to treat major depressive disorder and substance use disorder. It is also involved in the development of an M4 agonist program for the treatment of psychosis and related indications; and PDE4 inhibitor for the treatment of psychiatric, neuroinflammatory, and other disorders. Cerevel Therapeutics Holdings, Inc. was founded in 2018 and is headquartered in Cambridge, Massachusetts.

Cerevel Therapeutics Holdings, News
12/08/23 $19 Billion in a Week: AbbVie Makes Two Big Bets
12/07/23 Bain Capital Banks Massive Return on Cerevel Deal
12/07/23 Stocks to Watch Thursday: AbbVie, AMD, GameStop, Cerevel, JetBlue
12/07/23 AbbVie acquiring Cerevel Therapeutics in $8.7B deal
12/06/23 AbbVie to Buy Cerevel Therapeutics for $8.7 Billion
12/06/23 AbbVie to Acquire Cerevel Therapeutics in Transformative Transaction to Strengthen Neuroscience Pipeline
11/29/23 Cerevel Therapeutics to Host Investor Webcast on Tavapadon in Parkinson’s Disease
11/08/23 Cerevel Therapeutics to Present at Upcoming Investor Conferences
11/01/23 Cerevel Therapeutics Holdings Inc (CERE) Reports Q3 2023 Financial Results
11/01/23 Cerevel Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates
10/13/23 Cerevel Therapeutics to Report Third Quarter 2023 Financial Results and Business Updates on Wednesday, November 1, 2023
10/11/23 Cerevel Therapeutics Announces Pricing of $450 Million Public Offering of Common Stock
10/11/23 Cerevel Therapeutics Announces Proposed Public Offering of Common Stock
08/29/23 Cerevel Therapeutics to Present at Morgan Stanley 21st Annual Global Healthcare Conference
08/11/23 Insiders Buy the Dip in These 2 Beaten-Down Stocks, Analysts Say They Could Be Ready to Bounce Back — Here’s Why You Should Pay Attention
08/02/23 Cerevel Therapeutics Reports Second Quarter 2023 Financial Results and Business Updates
07/05/23 Cerevel Therapeutics to Report Second Quarter 2023 Financial Results and Business Updates on Wednesday, August 2, 2023
06/15/23 Cerevel Therapeutics Appoints Paul Burgess as Chief Business Development and Strategic Operations Officer
05/10/23 Cerevel Therapeutics Appoints Susan Altschuller, Ph.D. as Chief Financial Officer
05/03/23 Cerevel Therapeutics Appoints Ron Renaud as President and Chief Executive Officer and Reports First Quarter 2023 Financial Results
CERE Chatroom

User Image swingingtech Posted - 3 days ago

$ABBV $CERE https://wallstreetwaves.com/is-abbvie-stock-a-buy-now/

User Image swingingtech Posted - 4 days ago

$ABBV $PBYI $ACIU $CERE. https://wallstreetwaves.com/abbvie-abbv-announces-appointment-of-new-ceo-robert-michael/

User Image ChelseaMurphy289 Posted - 5 days ago

$CERE is on the rise, but COEP's anticipated surge based on analyst estimates suggests a compelling growth story.

User Image MergerObserver Posted - 5 days ago

$CERE $ABBV AbbVie’s proposed acquisition of Ceravel Therapeutics was approved by shareholders on Friday. Further, the parties each received a second request from the FTC in connection with the agency’s review of the deal. The parties continue to expect to close the deal in the middle of the year.

User Image swingingtech Posted - 1 week ago

$CERE $ABBV https://wallstreetwaves.com/cerevel-abbvie-get-ftc-second-requests-for-more-merger-info/

User Image maikelm82 Posted - 1 week ago

$IMGN acquisition completed by $ABBV next up is $CERE to be finalized for $45

User Image insiderbuyingselling Posted - 2 weeks ago

$CERE new insider selling: 2161 shares. http://insiderbuyingselling.com/?t=CERE

User Image insiderbuyingselling Posted - 2 weeks ago

$CERE new insider selling: 2506 shares. http://insiderbuyingselling.com/?t=CERE

User Image StoneFoxCapital Posted - 2 weeks ago

$ABBV game changer $IMGN $CERE https://seekingalpha.com/article/4667929-abbvie-game-changer

User Image Quantumup Posted - 2 weeks ago

UBS🏁 $AXSM Buy/$111~is bullish on Auvelity's launch/ $AXSM' pipeline opps w/ upcoming late-stage clinical readouts. UBS est $2.4B rev '29. Auvelity could become a leading brand in depression, generating $1B by '30. +VE P3 AD/narcolepsy data should drive stock OP. $krtx $bmy $cere $abbv

User Image PST_Markets Posted - 3 weeks ago

Surging 700% in just a few DAYS, this is the story of three insane trades that banked MILLIONS of dollars. $IMGN $ABBV $CERE $EYPT https://pennystocks.today/rampant-insider-trading-of-biotech-stocks/

User Image tomRussell80 Posted - 01/31/24

@Getgogreed @golfingarmyofone they guided previously first half 2024 - sama as $CERE

User Image Quantumup Posted - 1 month ago

Goldman Sachs⬆️ $NBIX $153 was $134/Buy comm opp4 crinecerfont has become more visible following success of Ph3 studies in CAH; looks4 cont'd Ingrezza OP 4Q23 rev-GS/Cons $510M/$504M&FY24-GS/Cons $2.13B/$2.11B); muscarinic space deals $ABBV $CERE- $BMY $KRTX provide proof2deep pipe.

User Image TalkMarkets Posted - 1 month ago

ABBV: This Top Biotech Just Went On A Buying Spree $ABBV Also $IMGN $AMGN $CERE $KRTX https://talkmarkets.com/content/stocks--equities/abbv-this-top-biotech-just-went-on-a-buying-spree?post=428928&userid=166882

User Image shortvolumes Posted - 1 month ago

2024-01-23 Short sale volume (not short interest) for $CERE is 37%. http://shortvolumes.com/?t=CERE via @shortvolumes

User Image rich54 Posted - 1 month ago

$FUSN Perceptive Advisors little record. $NBIX $CBAY $CERE https://www.tipranks.com/news/article/billionaire-joseph-edelman-snaps-up-these-2-biotech-stocks-heres-why-you-should-follow

User Image MergerObserver Posted - 1 month ago

$CERE $ABBV Cerevel Therapeutics has filed the definitive proxy for its proposed $8.1 billion acquisition by AbbVie. Shareholders are scheduled to vote at 9am ET on February 16, 2024. Regulatory Conditions: Cerevel and AbbVie voluntarily pulled and refiled HSR in respect to the US Federal Trade Commission’s review. The 30-day waiting period is now scheduled to expire on February 16, 2024, at 11:59 pm ET. Closing guidance: Mid 2024

User Image PST_Markets Posted - 1 month ago

Surging 700% in just a few DAYS, this is the story of three insane trades that banked MILLIONS of dollars. $IMGN $CERE $EYPT Find out how you can try to replicate them for yourselves 👀 Watch ⬇ https://youtu.be/JNLeeDGEuMU

User Image risenhoover Posted - 1 month ago

$CERE / Cerevel Therapeutics Holdings files form DEFM14A https://fintel.io/doc/sec-cerevel-therapeutics-holdings-inc-1805387-defm14a-2024-january-18-19740-4035?utm_source=stocktwits.com&utm_medium=referral&utm_campaign=filing

User Image risenhoover Posted - 1 month ago

$CERE / Cerevel Therapeutics Holdings files form PRER14A https://fintel.io/doc/sec-cerevel-therapeutics-holdings-inc-1805387-prer14a-2024-january-18-19740-5870?utm_source=stocktwits.com&utm_medium=referral&utm_campaign=filing

User Image StockInvest_us Posted - 1 month ago

Signal alert: $CERE - Undervalued https://stockinvest.us/l/C5YRtBvpqv

User Image Mergerbrief Posted - 1 month ago

$CERE $ABBV - HSR expires @ midnight mergerbrief.com

User Image Power2k Posted - 1 month ago

$ANVS If Buntanetap works for both PD and AD, this company is worth at least $15 billion. $ABBV spent $8.7 Billion acquiring $CERE which has a mediocre PD drug plus a few drug candidates for schizophrenia and psychiatric disorders. None of them comes close to AD in terms of market size or unmet medical need.

User Image TrendyChart Posted - 1 month ago

$CERE Bullish strokes adorn chart canvas. 📈 https://trendspider.com/?_go=options

User Image TrendyChart Posted - 1 month ago

$CERE The technical orchestra plays a tune of optimism on the stock chart, where the trend dances gracefully, and resistance trembles under its force. 📊 https://trendspider.com/?_go=options

User Image MergerObserver Posted - 1 month ago

$CERE $ABBV Preliminary proxy filed. Background: On October 19, 2023, AbbVie offered to acquire Cerevel for $35 per share. On October 27 Cerevel told AbbVie that this represented insufficient value for shareholders. On November 6 a large pharmaceutical company, “Party A”, expressed interest in a potential acquisition of Cerevel. On November 7 AbbVie submitted a revised proposal of $40 per share. On November 9 a large pharmaceutical company, “Party B”, discussed a potential deal. The same day, another large pharmaceutical company, “Party C”, also expressed interest in exploring a transaction. On November 17 AbbVie revised its proposal to $41.50 per share, which was later increased to $45 per share. Discussions continued through November and into December, and on December 4 Party C said it would not make a formal takeover bid above $40 per share. On December 6 Cerevel and AbbVie issued a joint press release announcing a deal at $45 per share.

User Image moneystreet Posted - 1 month ago

JPMorgan Healthcare Conference Gets Underway Monday #Bio Stocks in focus , $CERE $ABBV $SAVA $BION

User Image risenhoover Posted - 1 month ago

$CERE / Cerevel Therapeutics Holdings files form PREM14A https://fintel.io/doc/sec-cerevel-therapeutics-holdings-inc-1805387-prem14a-2024-january-05-19727-1620?utm_source=stocktwits.com&utm_medium=referral&utm_campaign=filing

User Image risenhoover Posted - 1 month ago

Insider N Anthony Coles reports selling 50,000 shares of $CERE for a total cost of $2,111,815.00 https://fintel.io/n/us/cere/coles-n-anthony?utm_source=stocktwits.com&utm_medium=referral&utm_campaign=insider

User Image ChartMill Posted - 1 month ago

$CERE: Kuehn Law Encourages $CERE, HA, IMGN, and WAVD Investors to Contact Law Firm https://www.chartmill.com/stock/quote/CERE/news?utm_source=prnews-2024-1-2-kuehn-law-encourages-cere-ha-imgn-and-wavd-investors-to-contact-law-firm&utm_medium=stocktwits&utm_campaign=pressRelease

Analyst Ratings
Mizuho Neutral Feb 16, 24
JP Morgan Neutral Dec 28, 23
Jefferies Hold Dec 22, 23
TD Cowen Market Perform Dec 8, 23
HC Wainwright & Co. Neutral Dec 7, 23
Piper Sandler Neutral Dec 7, 23
Cantor Fitzgerald Neutral Dec 7, 23
Morgan Stanley Overweight Nov 2, 23
Piper Sandler Overweight Sep 28, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
DiPietro Kenneth Chief Human Resource.. Chief Human Resources Officer Dec 22 Sell 41.45 8,000 331,600 24,663 12/27/23
DiPietro Kenneth Chief Human Resource.. Chief Human Resources Officer Dec 22 Option 3.5 8,000 28,000 32,663 12/27/23
Bodenrader Mark See Remarks See Remarks Dec 19 Sell 41.42 7,889 326,762 17,724 12/21/23
DiPietro Kenneth Chief Human Resource.. Chief Human Resources Officer Dec 19 Sell 41.42 6,256 259,124 24,663 12/21/23
Akamine Scott Chief Legal Officer Chief Legal Officer Dec 19 Sell 41.42 7,072 292,922 7,237 12/21/23
Sanchez Ramiro Chief Medical Office.. Chief Medical Officer Dec 19 Sell 41.42 10,152 420,496 14,673 12/21/23
ALTSCHULLER Susan Chief Financial Offi.. Chief Financial Officer Dec 19 Sell 41.42 13,808 571,927 16,913 12/21/23
Tregoning Kathleen See Remarks See Remarks Dec 19 Sell 41.42 6,288 260,449 7,516 12/21/23
Akamine Scott Chief Legal Officer Chief Legal Officer Dec 05 Sell 38.19 17,500 668,325 513 12/07/23
Akamine Scott Chief Legal Officer Chief Legal Officer Dec 05 Option 13.17 17,500 230,475 10,513 12/07/23
COLES N ANTHONY Director Director Nov 07 Sell 25.09 27,176 681,846 2,704 11/09/23
COLES N ANTHONY Director Director Nov 07 Option 3.5 27,176 95,116 2,804 11/09/23
COLES N ANTHONY Director Director Nov 02 Sell 25.31 100,000 2,531,000 2,704 11/06/23
COLES N ANTHONY Director Director Nov 02 Option 3.5 100,000 350,000 64,105 11/06/23
PERCEPTIVE ADVISORS LLC Director Director Oct 16 Buy 22.81 876,808 19,999,990 10,794,876 10/17/23
Renaud Ronald C JR President & CEO President & CEO Aug 03 Buy 23.9552 83,857 2,008,811 83,857 08/07/23
Burgess Paul D. See Remarks See Remarks Aug 04 Buy 22.9339 21,880 501,794 21,880 08/07/23
COLES N ANTHONY Director Director Jul 11 Sell 30.03 50,000 1,501,500 2,704 07/13/23
COLES N ANTHONY Director Director Jul 11 Option 3.5 50,000 175,000 52,704 07/13/23
COLES N ANTHONY CEO and Chairperson CEO and Chairperson Jun 01 Sell 32.6 50,000 1,630,000 2,704 06/05/23
COLES N ANTHONY CEO and Chairperson CEO and Chairperson Jun 01 Option 3.5 50,000 175,000 52,704 06/05/23
Bodenrader Mark See Remarks See Remarks Jun 01 Sell 32.95 1,895 62,440 5,522 06/05/23
COLES N ANTHONY CEO and Chairperson CEO and Chairperson Apr 11 Sell 25.06 50,000 1,253,000 2,704 04/13/23
COLES N ANTHONY CEO and Chairperson CEO and Chairperson Apr 11 Option 3.5 50,000 175,000 52,704 04/13/23
COLES N ANTHONY CEO and Chairperson CEO and Chairperson Feb 06 Sell 33.31 50,000 1,665,500 2,704 02/08/23
COLES N ANTHONY CEO and Chairperson CEO and Chairperson Feb 06 Option 3.5 50,000 175,000 52,704 02/08/23
COLES N ANTHONY CEO and Chairperson CEO and Chairperson Jan 05 Sell 30.33 50,000 1,516,500 2,704 01/06/23
COLES N ANTHONY CEO and Chairperson CEO and Chairperson Jan 05 Option 3.5 50,000 175,000 52,704 01/06/23
COLES N ANTHONY CEO and Chairperson CEO and Chairperson Dec 09 Option 3.5 50,000 175,000 52,704 12/13/22
COLES N ANTHONY CEO and Chairperson CEO and Chairperson Dec 09 Sell 26.86 50,000 1,343,000 2,704 12/13/22
PERCEPTIVE ADVISORS LLC Director Director Aug 16 Buy 35.00 1,425,000 49,875,000 6,511,727 08/18/22
Renger John Chief Scientific Off.. Chief Scientific Officer Aug 05 Option 3.5 30,000 105,000 12,704 08/09/22
Renger John Chief Scientific Off.. Chief Scientific Officer Aug 05 Sell 35.13 30,000 1,053,900 2,704 08/09/22
Akamine Scott Chief Legal Officer Chief Legal Officer Aug 08 Option 13.17 10,000 131,700 10,000 08/09/22
Akamine Scott Chief Legal Officer Chief Legal Officer Aug 08 Sell 40 10,000 400,000 08/09/22
Ceesay Abraham President President Aug 05 Sell 36.58 57,635 2,108,288 08/09/22
Ceesay Abraham President President Aug 05 Option 13.17 57,635 759,053 19,211 08/09/22
Renger John Chief Scientific Off.. Chief Scientific Officer Jul 05 Option 3.5 26,105 91,368 3,809 07/07/22
Renger John Chief Scientific Off.. Chief Scientific Officer Jul 05 Sell 31.25 26,105 815,781 2,704 07/07/22
Renger John Chief Scientific Off.. Chief Scientific Officer Apr 13 Option 3.5 45,000 157,500 46,980 04/15/22
Renger John Chief Scientific Off.. Chief Scientific Officer Apr 13 Sell 34.65 45,000 1,559,250 1,980 04/15/22
Renger John Chief Scientific Off.. Chief Scientific Officer Mar 16 Option 3.5 45,000 157,500 21,980 03/18/22
Renger John Chief Scientific Off.. Chief Scientific Officer Mar 16 Sell 31.25 45,000 1,406,250 1,980 03/18/22
Renger John Chief Scientific Off.. Chief Scientific Officer Feb 09 Option 3.5 25,000 87,500 26,980 02/11/22
Renger John Chief Scientific Off.. Chief Scientific Officer Feb 09 Sell 30 25,000 750,000 1,980 02/11/22
Renger John Chief Scientific Off.. Chief Scientific Officer Dec 15 Option 3.5 37,700 131,950 9,102 12/17/21
Renger John Chief Scientific Off.. Chief Scientific Officer Dec 15 Sell 31.67 37,700 1,193,959 1,980 12/17/21
PERCEPTIVE ADVISORS LLC Director Director Aug 25 Buy 27.36 175,585 4,804,006 5,018,680 08/25/21